NASDAQ$INCY
Incyte Corp. · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Incyte reported strong revenue growth, driven by Jakafi demand and the launches of Monjuvi and Pemazyre, while also achieving positive results across multiple late-stage programs.
Incyte reported its 2020 fourth quarter and year-end financial results, highlighting strong revenue growth driven by Jakafi and the launches of Monjuvi and Pemazyre. The company also provided 2021 financial guidance and updates on key clinical programs, anticipating regulatory decisions on seven applications and a potential U.S. launch of ruxolitinib cream.
- Revenue growth was strong, driven by demand for Jakafi.
- Monjuvi and Pemazyre launches continue to gain momentum.
- Positive results were announced across multiple late-stage programs.
- Seven applications are seeking approval in 2021.
Headline financials
Revenue & EPS history
Incyte · Revenue · Quarterly
$790M
Revenue by segment
Incyte · $775M total across 5 segments · Q3 2023
- Jakafi$636M+2.7%82.1%
- Opzelura$91.8M+140.8%11.9%
- Iclusig$27.7M+6.9%3.6%
- Pemazyre$18.9M-19.1%2.4%
- Zynyz$98—0.0%
Forward guidance
Incyte provided its 2021 financial guidance, which includes net product revenue guidance for Jakafi and other Hematology/Oncology products. The guidance does not include revenue from potential new product launches but includes costs to support the potential launches of ruxolitinib cream, pemigatinib, and tafasitamab.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
50%
32 / 64 earnings
Positive
+18.2%
Q1 2012
Best reaction
-25.8%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | +1.2% | +0.8% | |
| Q4 2025 | -8.2% | -7.3% | -15.6% | |
| Q3 2025 | -1.6% | +0.4% | +13.5% | |
| Q1 2025 | +1.5% | +5.1% | +11.0% | |
| Q4 2024 | -7.9% | -5.0% | -8.6% | |
| Q3 2024 | +12.5% | +15.9% | +14.9% | |
| Q2 2024 | -5.1% | -6.0% | -3.9% | |
| Q1 2024 | +0.7% | +2.3% | +9.0% | |
| Q4 2023 | +0.1% | +0.2% | +1.2% | |
| Q3 2023 | +4.2% | +5.2% | +4.2% | |
| Q2 2023 | +3.1% | -0.1% | +1.3% | |
| Q1 2023 | -9.7% | -11.7% | -18.4% | |
| Q4 2022 | -4.6% | -6.0% | -13.6% | |
| Q3 2022 | +3.8% | +4.0% | +8.5% | |
| Q2 2022 | -6.3% | -6.8% | -7.8% | |
| Q1 2022 | +6.1% | -1.1% | -1.9% | |
| Q4 2021 | -6.9% | -9.0% | +0.2% | |
| Q3 2021 | -3.7% | -2.1% | -3.9% | |
| Q2 2021 | -1.4% | -2.8% | -1.6% | |
| Q1 2021 | -5.0% | -3.3% | -3.1% | |
| Q4 2020 | -9.0% | -9.9% | -15.1% | |
| Q3 2020 | -8.8% | -8.9% | -8.8% | |
| Q2 2020 | -4.1% | -4.8% | -10.0% | |
| Q1 2020 | -4.9% | -5.0% | -7.1% | |
| Q4 2019 | +3.5% | +4.6% | -2.6% | |
| Q3 2019 | +4.8% | +4.7% | +17.9% | |
| Q2 2019 | +5.8% | +4.0% | +2.7% | |
| Q1 2019 | +6.1% | +11.7% | +5.9% | |
| Q4 2018 | +3.8% | +3.7% | +4.6% | |
| Q3 2018 | +2.4% | +6.5% | +2.3% | |
| Q2 2018 | -4.4% | -8.1% | +7.4% | |
| Q1 2018 | -1.4% | +0.3% | +10.2% | |
| Q4 2017 | -2.4% | -3.0% | +2.1% | |
| Q3 2017 | -5.5% | -8.0% | -13.3% | |
| Q2 2017 | -5.7% | -3.4% | +3.1% | |
| Q1 2017 | -0.6% | -2.8% | +6.7% | |
| Q4 2016 | -0.2% | -0.5% | +22.5% | |
| Q3 2016 | +0.2% | +0.7% | +14.9% | |
| Q2 2016 | -5.2% | -7.9% | -7.4% | |
| Q1 2016 | +4.0% | — | — | |
| Q4 2015 | -5.5% | — | — | |
| Q3 2015 | -2.9% | — | — | |
| Q2 2015 | +6.7% | — | — | |
| Q1 2015 | -3.3% | — | — | |
| Q4 2014 | -0.0% | — | — | |
| Q3 2014 | +15.9% | — | — | |
| Q2 2014 | -4.9% | — | — | |
| Q1 2014 | +6.3% | — | — | |
| Q4 2013 | +0.2% | — | — | |
| Q3 2013 | +4.7% | — | — | |
| Q2 2013 | +14.7% | — | — | |
| Q1 2013 | +3.3% | — | — | |
| Q4 2012 | +18.0% | — | — | |
| Q3 2012 | +6.8% | — | — | |
| Q2 2012 | -25.8% | — | — | |
| Q1 2012 | +18.2% | — | — | |
| Q4 2011 | +1.7% | — | — | |
| Q3 2010 | +0.9% | — | — | |
| Q3 2011 | +0.9% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2010 | +6.0% | — | — | |
| Q1 2010 | +6.0% | — | — | |
| Q1 2011 | +6.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro